Daiichi Sankyo Expands European Sales Presence By Hiring 130 Merck KGaA Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Goal is a 70/30 split of ROW and Japanese revenues, firm says.
You may also be interested in...
Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Daiichi will pay $4.6 billion for stake in generics marketer.